Tumor Carbohydrate Antigens and Strategies to Develop Cancer Vaccines and Drugs

查看全文 作　　者：LIU [1]Min;PAN [1]Qin;LUO [1]Fengling;MEYERS [2]Craig;ZHANG Xiao-[1]Lian 机构地区：[1]State Key Laboratory of Virology/Hubei Province Key Laboratory of Allergy and Immunology/School of Medicine,Wuhan University;[2]Department of Microbiology and Immunology, College of Medicine, Pennsylvania State University 出　　处：《Wuhan University Journal of Natural Sciences》索引2013年第18卷第1期,共8页 基　　金：Supported by the National Outstanding Youth Foundation of China (81025008);the National Natural Science Foundation of China (30921001,30800038, 31270176 and 81000714);the National Grand Program on Important Infectious Disease (2012ZX10003002-015);the National Basic Research Program of China (973 Program, 2009CB522507 and 2012CB720604) 摘　　要：Certain carbohydrate antigens of malignantly transformed cells have been identified as markers for the onset of cancer and have become targets for the development of anticancer vaccine therapies. For tumor antigens, many carbohydrate antigens belong to T-independent (TI) antigens. Carbohydrate conjugated to protein carriers can switch TI antigen to a T-dependent (TD) antigen. Attempts to add an innate immune response element (such as Toll-like receptor ligand) to carbohydrate TI-antigens have also been studied. Glycosylation inhibitors or small interfering RNA have also been used for antitumor and/or antiviral agents. This review aims at describing the vast spectrum of tumor carbohydrate antigens and strategies to develop cancer vaccines and drugs. 关 键 词：carbohydrate antigen cancer vaccine cancer ther-apy carbohydrate vaccine carbohydrate drug